Postmarket surveillance for drug-eluting coronary stents: A comprehensive approach

Circulation

Volumn 113, Issue 6, 2006, Pages 891-897

  Baim, Donald S ^a   Mehran, Roxana ^b   Kereiakes, Dean J ^c   Gross, Thomas P ^d   Simons, Michael ^e   Malenka, David ^e   Kaplan, Aaron V ^e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Howard Hughes Medical Institute   (United States)

^c The Carl & Edyth Lindner Center for Research & Education   (United States)

^d CENTER FOR DEVICES AND RADIOLOGICAL HEALTH   (United States)

^e DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Angioplasty; Coronary disease; Postmarket surveillance; Regulatory policy; Stents

Indexed keywords

METAL; PACLITAXEL; RAPAMYCIN; DRUG;

ACCURACY; BALLOON CATHETER; CORONARY ARTERY DISEASE; CORONARY STENT; COST; DRUG ELUTING STENT; EVALUATION; FOOD AND DRUG ADMINISTRATION; HUMAN; MARKETING; MONEY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REGISTER; REVIEW; RISK REDUCTION; SAFETY; TREATMENT INDICATION; DRUG DELIVERY SYSTEM; INFORMATION PROCESSING; METHODOLOGY; STENT;

DATA COLLECTION; DRUG DELIVERY SYSTEMS; HUMANS; PHARMACEUTICAL PREPARATIONS; PRODUCT SURVEILLANCE, POSTMARKETING; STENTS;

EID: 33644852941     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.569657     Document Type: Review

References (31)

1. Kaplan AV, Baim DS, Smith JJ, Feigal DA, Simons MS, Jefferys D, Fogarty TJ, Kuntz RE, Leon MB. Medical device development: from prototype to regulatory approval. Circulation. 2004;109:3068-3072.
2. Mehran R, Leon MB. Feigal DA, Jefferys D, Simons MS, Chronos N, Fogarty TJ, Kuntz RE, Baim DS, Kaplan AV. Post-market approval surveillance: a call for a more integrated and comprehensive approach. Circulation. 2004;109:3073-3077.
3. Annual Report. New Brunswick, NY: Johnson & Johnson; 2003.
4. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IMF, Seixas AC, Staico R, Mattos LA, Sousa AGMR, Falotico R, Jaeger J, Popma JJ, Serruys PWS. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 2001;103:192-195.
5. Morice M-C, Serruys PW, Sousa E, Fajadet J, Hayashi E, Perin M, Colombo A, Schule G, Barragan P, Guagliumi G, Molnar F, Falotico R, for the RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780.
6. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE, for the SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323.
7. FDA announcement of Cypher approval, April 24, 2003. Available at: http://www.fda.gov/bbs/topics/NEWS/2003/NEW00896.htmlAnnouncement of Cypher approval. Accessed April 27, 2005.
8. Donohue D. "Dear Colleague" letter. Miami Lakes, Fla: Cordis/A Johnson & Johnson Co; July 7, 2003.
9. Cordis corporation issues a health care professional letter regarding the CYPHER stent. FDA News, July 8,2003. Available at: http://www.fda.gov/bbs/ topics/NEWS/2003/NEW00919.html. Accessed February 8, 2005.
10. FDA public health Web notification: information for physicians on sub-acute thromboses (SAT) and hypersensitivity reactions with use of the Cordis CYPHER™ coronary stent. Issued October 29, 2003. Available at: http://www.fda.gov/cdrh/safety/cypher.html. Accessed February 8, 2005.
11. FDA public health Web notification: updated information for physicians on sub-acute thromboses (SAT) and hypersensitivity reactions with use of the Cordis CYPHER™ coronary stent. Issued November 25, 2003. Available at: http://www.fda.gov/cdrh/safety/cypher2.html. Accessed May 28, 2005.
12. Jeremias A, Sylvia B, Bridges J, Kirtane AJ, Bigelow B, Pinto DS. Ho KKL, Cohen DJ, Garcia LA, Cutlip DE, Carrozza JP. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation. 2004;109:1930-1932.
13. Ong ATL, Hove A, Aoki J, van Mieghem CAG, Granillo GAR, Sonnenschein K, Regar E, McFadden EP, Sianos G, van der Giessen WJ, de Jaegere PPT, de Feyter P, van Domburg RT, Serruys PW. Thirty-day incidence and six-month outcome of thrombotic stent occlusion following bare metal, sirolimus or paclitaxel stent implantation. J Am Coll Cardiol. 2005;45:944-950.
14. Final update of information for physicians on sub-acute thromboses (SAT) and hypersensitivity reactions with use of the Cordis CYPHER™ sirolimus-eluting coronary stent, updated October 18, 2004. Available at: http://www.fda.gov/cdrh/safety.html. Accessed February 9, 2005.
15. Schultz DG. Letter approving P030025 Taxus™ Express2™ paclitaxel-eluting coronary stent system (Monrail and Over-the-Wire). Department of Health & Human Services, March 4, 2004. Available at: http://www.fda.gov/cdrh/pdf3/p030025.html. Accessed April 16, 2005.
16. Boston Scientific announces preliminary information on U.S. Taxus sales for April, Natick, MA (May 4, 2004): Boston Scientific Corporation. Available at: http://www.bostonscientific.com/common_templates/articleDisplayTemplate. jhtml?task=tskPressRelease.jhtml§ionId=2&relId=24,25&uniqueId= ABPR4984. Accessed February 9, 2005.
17. Boston Scientific recalls 200 Taxus Stent Systems, Natick, MA (July 22, 2004). Available at: http://www.bostonscientific.com/common_templates/ articleDisplayTemplate.jhtml?task=tskPressRelease.jhtml§ionId= 2&relId=24,25&uniqueId=ABPR5408&clickType=endeca& acceptedWarning=PR. Accessed February 9, 2005.
18. Boston Scientific Expands Recall of Taxus Coronary Stent System, Natick, MA (August 5, 2004). Available at: http://www.bostonscientific.com/ common_templates/articleDisplayTemplate.jhtml?task=tskPressRelease. jhtml§ionId=2&relId=24,25&uniqueId=ABPR5408&clickType= endeca&acceptedWarning=PR. Accessed February 9, 2005.
19. Nudell B. BSX: Taxus market share returns: prospect of share repurchase offsets increased re-investment. Bernstein Research Call. September 2, 2004.
20. Kerber R, and Krasner J. Boston Scientific collects stents, offers assurances. Boston Globe. July 20, 2004: A1.
21. Title 21, US Code of Federal Regulations. Part 803.
22. Samore MH, Evans RS, Lassen A, Gould P, Lloyd J, Gardner RM, Abouzelof R, Taylor C, Woodbury DA, Willy M, Bright RA. Surveillance of medical device-related hazards and adverse events in hospitalized patients. JAMA. 2004;291:325-334.
23. McGrath PD, Wennberg DE, Dickens JD Jr, Siewers AE, Lucas FL, Malenka DJ, Kellett MA Jr, Ryan TJ Jr. The relation between operator and hospital volume following percutaneous coronary interventions in the era of the coronary stent. JAMA. 2000;284:3139-3144.
24. McGrath PD, Malenka DJ, Wennberg DE, Shubrooks SJ Jr, Bradley WA, Robb JF, Kellett MA Jr, Ryan TJ Jr, Hearne MJ, Hettleman B, O'Mear JO, Ver Lee P, Watkins MW, Piper WD, O'Connor GT, for the Northern New England Cardiovascular Disease Study Group. Changing outcomes in percutaneous coronary interventions: a study of 34,752 procedures in northern New England, 1990-1997. J Am Coll Cardiol. 1999;34:674-680.
25. Maynard C, Goss JR, Malenka DJ, Reisman M, for the Clinical Outcomes Assessment Program. Adjusting for patient differences in predicting hospital mortality for percutaneous coronary interventions in the Clinical Outcomes Assessment Program. Am Heart J. 2003;145:658-664.
26. Williams DO, Holubkov R, Yeh W, Bourassa MG, Al-Bassam M, Block PC, Coady P, Cohen H, Cowley M, Dorros G, Faxon D, Holmes DR, Jacobs A, Kelsey SF, King SB III, Myler R, Slater J, Stanek V, Vlachos HA, Detre KM. Percutaneous Coronary intervention in the current era compared with 1985-1986: the National Heart, Lung, and Blood Institute registries. Circulation. 2000;102:2945-2951.
27. Anderson HV, Shaw RE, Brindis RG, Hewitt K, Krone RJ, Block PC, McKay CR, Weintraub WS. A contemporary overview of percutaneous coronary interventions: the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). J Am Coll Cardiol. 2002;39:1096-1103.
28. Gershlick AH, Guagliumi G, Guyon P, Lotan C, Schofer J, Seth A, Sousa E, Urban P, Wijns W. Comparison of outcomes for sirolimus-eluting stent in the E-Cypher Registry with those from randomised controlled trials (SIRIUS). J Am Coll Cardiol. 2005;45:50A. Abstract.
29. Niemela K, Chevalier B, Stoerger H, Bilodeau L, Brito F, Russell M. Taxus Express stent usage patterns and clinical outcomes: twelve-month results from the European subset of the Global Milestone-II Registry. J Am Coll Cardiol. 2005;45:50A. Abstract.
30. Mayo E. The Human Problems of an Industrial Civilisation. New York, NY: MacMillan Co; 1933:chap 3.
31. Urban P. e-Cypher registry: 6 month report. Available at: http://www.tctmd.com/expert-presentations/multi-slide.html?product_id=6603. Accessed May 1, 2005.